Glaxosmithkline Pharmaceuticals Ltd

Glaxosmithkline Pharmaceuticals Ltd demonstrated robust intraday performance on 22 Jan 2026, surging to an intraday high of Rs 2,391.35, marking a 5.16% increase. The stock outperformed its sector and the broader market, reflecting strong trading momentum amid a mixed market backdrop.

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Glaxosmithkline Pharmaceuticals Ltd is rated Sell by MarketsMOJO. This rating was last updated on 20 Oct 2025, reflecting a shift in the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 09 January 2026, providing investors with the latest insights into its performance and valuation.

Glaxosmithkline Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Oct 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 28 December 2025, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Glaxosmi. Pharma has experienced a revision in its market evaluation, reflecting shifts in key analytical parameters including valuation, technical outlook, and financial trends. This adjustment highlights evolving investor perspectives on the midcap pharmaceutical company amid a complex sector environment.

Glaxosmithkline Pharmaceuticals has experienced a shift in its technical momentum, with recent evaluation adjustments indicating a bearish trend across several key indicators. Despite this, the stock's year-to-date returns continue to outpace the broader Sensex, reflecting a complex interplay between price action and market sentiment within the Pharmaceuticals & Biotechnology sector.

Glaxosmi. Pharma has undergone a revision in its market evaluation, reflecting shifts in key analytical parameters that influence investor sentiment and stock performance within the Pharmaceuticals & Biotechnology sector.

GlaxoSmithKline Pharmaceuticals Ltd. reported a modest net profit of ₹257.49 crores for Q2 FY26, marking a 25.60% quarter-on-quarter increase but a mere 1.98% year-on-year growth. The pharmaceutical major, with a market capitalisation of ₹44,633 crores, continues to grapple with anaemic top-line expansion whilst maintaining its premium valuation at 47 times trailing earnings. The stock has declined 2.32% following the results announcement, trading at ₹2,599.75 and reflecting investor concerns about the sustainability of its lofty multiples in the face of stagnating revenue growth.

Glaxosmithkline Pharmaceuticals has recently experienced an evaluation adjustment, indicating a shift in its technical indicators. While the stock has performed well year-to-date, its annual return is modest compared to profit growth. The company faces challenges with a high Price to Book Value ratio and flat quarterly results.

GlaxoSmithKline Pharmaceuticals has recently experienced a revision in its evaluation, reflecting changes in technical indicators. The stock has shown significant volatility over the past year, with a year-to-date return of 22.19%, outperforming the Sensex. However, its five-year performance has lagged behind the index.

Glaxosmithkline Pharmaceuticals has recently encountered a Death Cross, signaling potential bearish momentum. With a market capitalization of Rs 46,502.00 Cr and a P/E ratio of 49.38, the stock has outperformed the Sensex year-to-date but faces short-term challenges, including recent declines and bearish technical indicators.